Trials

Category / Pharmaceuticals & Biotech / Trials

Pherin Pharmaceuticals Reports Favorable Clinical, Regulatory, and Intellectual Property Actions on Novel Intranasal Medication for Acute Treatment of Social Anxiety Disorder and Issuance of Patents in the U.S.A. and Other Major Countries

LOS ALTOS, CA: ...

International Stem Cell Corp to Participate in Fifth Annual LD Micro Conference

CARLSBAD, CA: ...

WorldCare Clinical Expands Globally With New Offices Across Europe, S. America and Asia Pacific

BOSTON, MA: Leverages Established Clinical Infrastructure to Facilitate Real-Time Global Site Support ...

Last Chance to Attend 'Clinical Trials in Georgia' Conference on Nov. 2, 2012

ATLANTA, GA: Special Track for Principal Investigators Offers CME Credits ...

Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law")

GHENT, BELGIUM: Regulated Information ...

Tonix Pharmaceuticals Confirms Clinical Utility of TNX-102 Sublingual Tablet

NEW YORK, NY: Study Demonstrated Desirable Pharmacokinetic Profile With Rapid Absorption Well-Suited for Bedtime Use ...

Biota Announces Approval of Definitive Merger Agreement by Nabi Shareholders

MELBOURNE, AUSTRALIA: ...

Peregrine Pharmaceuticals Provides Update on Corporate Activities

TUSTIN, CA: Company Replaces Prior Loan Facility With Over $14 Million in Financing Proceeds Received Since September 27th; Growing Contract Manufacturing Business Remains on Track for Record Revenue Year; Multip ...

Clinical Trials Going Active for Cellceutix Anti-Cancer Drug Kevetrin

BEVERLY, MA: ...

Threshold Pharmaceuticals Announces Presentations on TH-302 in Pancreatic Cancer and Glioblastoma at ESMO

SOUTH SAN FRANCISCO, CA: ...

Interim Data From Peregrine's Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavitiximab-Containing Arms

TUSTIN, CA: ...

Peregrine to Present at Stifel Nicolaus Healthcare Conference September 5, 2012 at 2:40 PM EDT

TUSTIN, CA: ...

Boston Therapeutics Reports Second Quarter and Six Months 2012 Financial Results

MANCHESTER, NH: Initiated launch of SUGARDOWN(R) in the U.S. at the Endocrinology Annual Meeting; SUGARDOWN(R) Sales Increased 845% in the First Half of 2012; Completed Patient Enrollment for Phase II PAZ320 Clinical ...

Sarepta Therapeutics to Present Company Overview at the 32nd Canaccord Genuity Annual Growth Conference

CAMBRIDGE, MA: Webcast Accessible via Sarepta Therapeutics Website ...

Agennix AG Reports Financial Results for Second Quarter and First Half of 2012

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX: ...

Sarepta Announces Conference Call and Webcast on Tuesday, July 24, 2012, to Discuss 36-Week 6-Minute Walk Test Results From the Phase IIb DMD Study

CAMBRIDGE, MA: ...

Full Spectrum Genetics and BioBlocks Enter Collaboration to Discover Novel Small Molecule Therapeutics That Inhibit a Commercially Validated Cancer Target

SOUTH SAN FRANCISCO, CA and SAN DIEGO, CA: ...

Prana to Present at the UBS Australian Healthcare Conference in Sydney and the Australian Life Science Investment Showcase in New York